The drugmaker had been reluctant to project beyond 2023, particularly after its initial estimate for Humira's 2018 loss of exclusivity in Europe turned out to be too optimistic.
from Section Page News - Modern Healthcare https://ift.tt/3tC1GCS
via IFTTT
No comments:
Post a Comment